Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study
暂无分享,去创建一个
L. Risch | P. Vernazza | M. Schlegel | S. Güsewell | S. Kuster | C. Kahlert | C. Strahm | P. Kohler | D. Vuichard-Gysin | A. Friedl | A. Cusini | A. Brucher | M. Ruetti | R. Stocker | U. Besold | A. McGeer | J. C. Möller | S. Goppel | Elisabeth Möller | Manuela Ortner
[1] C. Howald,et al. Prevalence of post-COVID Condition 12 Weeks after Omicron Infection Compared to Negative Controls and Association with Vaccination Status. , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] J. Steinacker,et al. Post-acute sequelae of covid-19 six to 12 months after infection: population based study , 2022, BMJ.
[3] Christopher J. L. Murray,et al. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. , 2022, JAMA.
[4] James N. Druckman,et al. Prevalence and Correlates of Long COVID Symptoms Among US Adults , 2022, JAMA network open.
[5] Sebastian F N Bode,et al. Long COVID symptoms in exposed and infected children, adolescents and their parents one year after SARS-CoV-2 infection: A prospective observational cohort study , 2022, eBioMedicine.
[6] L. Borrell,et al. The epidemiology of long COVID in US adults two years after the start of the US SARS-CoV-2 pandemic , 2022, medRxiv.
[7] R. Cox,et al. Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study , 2022, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.
[8] Juarez Antônio Simões Quaresma,et al. Sociodemographic Characteristics and Comorbidities of Patients With Long COVID and Persistent Olfactory Dysfunction , 2022, JAMA network open.
[9] P. Heuschmann,et al. Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study , 2022, eClinicalMedicine.
[10] Y. Nakagama,et al. Detecting Waning Serological Response with Commercial Immunoassays: 18-Month Longitudinal Follow-up of Anti-SARS-CoV-2 Nucleocapsid Antibodies , 2022, Microbiology spectrum.
[11] D. Needham,et al. Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID) , 2022, BMC Medicine.
[12] M. Rescigno,et al. Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers. , 2022, JAMA.
[13] Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19 , 2022, The Journal of Emergency Medicine.
[14] H. Goossens,et al. Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up , 2022, BMJ Open.
[15] P. Weihe,et al. Long COVID in the Long Run—23-Month Follow-up Study of Persistent Symptoms , 2022, Open forum infectious diseases.
[16] C. Steves,et al. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2 , 2022, The Lancet.
[17] Z. Al-Aly,et al. Long COVID after breakthrough SARS-CoV-2 infection , 2022, Nature Medicine.
[18] N. Ohmagari,et al. Post COVID-19 condition of the Omicron variant of SARS-CoV-2 , 2022, Journal of Infection and Chemotherapy.
[19] A. Iwasaki,et al. Unexplained post-acute infection syndromes , 2022, Nature Medicine.
[20] S. Bhatt,et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study , 2022, The Lancet.
[21] L. Risch,et al. Symptoms compatible with long-COVID in healthcare workers with and without SARS-CoV-2 infection - results of a prospective multicenter cohort , 2021, medRxiv.
[22] J. Geddes,et al. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19 , 2021, PLoS medicine.
[23] U. Merle,et al. Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] Michelle A. Williams,et al. Confronting Our Next National Health Disaster - Long-Haul Covid. , 2021, The New England journal of medicine.
[25] S. Ladhani,et al. Causation or confounding: why controls are critical for characterizing long COVID , 2021, Nature Medicine.
[26] L. Risch,et al. Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19—a prospective multicenter cohort study , 2021, BMC Medicine.
[27] David A. Drew,et al. Attributes and predictors of long COVID , 2021, Nature Medicine.
[28] P. Findeisen,et al. Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay , 2021, Journal of Virological Methods.
[29] F. Pitta,et al. Construct validity of the Post-COVID-19 Functional Status Scale in adult subjects with COVID-19 , 2021, Health and Quality of Life Outcomes.
[30] L. Risch,et al. Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers – A multicentre cross-sectional study , 2020, Clinical Microbiology and Infection.
[31] M. Endres,et al. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19 , 2020, European Respiratory Journal.
[32] P. Magnus,et al. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine. , 2015, Vaccine.
[33] B. Löwe,et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. , 2006, Archives of internal medicine.
[34] R. Spitzer,et al. The PHQ-9 , 2001, Journal of General Internal Medicine.
[35] Y. Benyamini,et al. Self-rated health and mortality: a review of twenty-seven community studies. , 1997, Journal of health and social behavior.
[36] N. Larocca,et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. , 1989, Archives of neurology.
[37] P. White,et al. Risk and predictors of fatigue after infectious mononucleosis in a large primary-care cohort. , 2006, QJM : monthly journal of the Association of Physicians.